Date: 2015-10-01
Type of information: Nomination
Compound:
Company: Synthetic Biologics (USA - MD)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 1, 2015, Synthetic Biologics, a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that Raymond D. Stapleton, PhD, has joined the Company as Senior Vice President, Manufacturing. Dr. Stapleton will lead the manufacturing team as the Company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs, and continues to move its monoclonal antibody (mAb) program forward to address Pertussis (whooping cough).
Dr. Stapleton is a pharmaceutical and biotechnology executive with over 15 years of experience at Merck & Co, in manufacturing, operations, quality, science, technology, engineering and process development. He most recently served as Executive Director, Global Vaccine Technology and Engineering. During his tenure at Merck, Dr. Stapleton contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including Isentress® (oral solid dosage for AIDs), Gardasil® (HPV vaccine), Keytruda® (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy Mevacor® (lovastatin).
Dr. Stapleton earned a PhD in microbial ecology from The Center for Environmental Biotechnology at The University of Tennessee, Knoxville, and a BS degree in biology from Mary Washington College. Subsequently, he was the recipient of an Alexander Hollaender Fellowship for post-doctoral studies in the Environmental Science Division at Oak Ridge National Laboratory. Dr. Stapleton has served for 10 years as a member of the Journal of Industrial Microbiology and Biotechnology review board and is an ad hoc reviewer for several journals including Environmental Science and Technology, Antonie von Leeuwenhook, and Enzyme and Microbial Technology. He has co-edited a book, and co-authored patents, as well as several peer-reviewed manuscripts and presentations.
Financial terms:
Latest news:
